Please login to the form below

Not currently logged in

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer’s phase III programme will test the Spark Therapeutics-developed compound after it gathers safety and efficacy data of current factor IX prophylaxis replacement therapy as a lead-in study. ... We look forward to the opportunity to continue the

Latest news

More from news
Approximately 8 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

  • The rise of real-world evidence The rise of real-world evidence

    Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

  • Deal Watch December 2016 Deal Watch December 2016

    and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m. ... The size of the deals signed by AstraZeneca with Bicycle Therapeutics, by Spark with Selecta Biosciences and by Celgene with Evotec suggest that their technologies

  • Deal Watch August 2016 Deal Watch August 2016

    $14bn, antibiotic business interests from AstraZeneca for $1.4bn and Bamboo Therapeutics for $645m. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....